Multi-institutional, prospective study of a combination therapy with androgen deprivation and external beam radiation therapy for hormone-sensitive metastatic prostate cancer

Multi-institutional, prospective study of a combination therapy with androgen deprivation and external beam radiation therapy for hormone-sensitive metastatic prostate cancer - Multi-institutional, prospective study of a combination therapy with androgen deprivation and external beam radiation therapy for hormone-sensitive metastatic prostate cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000033226

Enrollment

Registered

2018-07-09

Start date

2018-07-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

Extra beam radiation therapy(EBRT)

intervention of EBRT for the prostate from 3 to 6 months after androgen deprivation therapy

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1, metastatic prostate cancer 2, StageIV,(TMN;Tany, N1 and/or M1) 3, Performance status 0-1(ECOG PS) 4, Age >= 20, <=85

Exclusion criteria

Exclusion criteria: 1, Had a prior malignancy. (Any other cancer for which treatment has been completed >= 5 years is allowed). 2, Other pathological findings except for aciner adenocarcinoma. 3, Use of steroid agents

Design outcomes

Primary

Measure	Time frame
Biochemical progression free survival	—

Secondary

Measure	Time frame
Overall survival Clinical progression-free survival Cancer specific survival Quality of life Adverse events	—

Countries

Japan

Contacts

Public ContactKawamorita Naoki

Tohoku University Hospital Urology

kawamorita@uro.med.tohoku.ac.jp022-717-7278

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026